Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.57 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.57 |
| ▸ | CASP1 | P29466 | 4/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | CASP9 | P55211 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | CPA2 | P48052 | 1/20 | 0.46 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7277693 | 0.99 | BACE1 (0.58) | BACE1BACE2CASP1OPRD1CASP3 | |
| SCHEMBL7277216 | 0.97 | BACE1 (0.58) | BACE1BACE2CASP1OPRD1CASP3 | |
| SCHEMBL7165559 | 0.91 | CASP1 (0.60) | BACE1BACE2CASP1CASP3CASP7 | |
| SCHEMBL7287204 | 0.89 | CASP1 (0.49) | BACE1BACE2CASP1OPRD1CASP3 | |
| SCHEMBL7284988 | 0.89 | CASP1 (0.49) | BACE1BACE2CASP1OPRD1CASP3 | |
| SCHEMBL17429544 | 0.88 | CASP1 (0.49) | BACE1BACE2CASP1OPRD1CASP3 | |
| SCHEMBL7164794 | 0.88 | CASP1 (0.57) | BACE1BACE2CASP1CASP3CASP7 | |
| SCHEMBL7275856 | 0.86 | CASP1 (0.49) | BACE1BACE2CASP1OPRD1CASP3 | |
| SCHEMBL24310825 | 0.84 | CASP1 (0.63) | BACE1BACE2CASP1OPRD1CASP3 | |
| SCHEMBL18087495 | 0.84 | CASP1 (0.63) | BACE1BACE2CASP1OPRD1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9956260-B1 | Treatment of HIV-1 infection and AIDS | THE J. DAVID GLADSTONE INSTITUTES (US) | 2018-05-01 | — | — | US | disclosed |
| US-20150343011-A1 | Treatment Of HIV-1 Infection And AIDS | THE J. DAVID GLADSTONE INSTITUTES | 2015-12-03 | — | — | US | disclosed |
| US-20100040607-A1 | Combination Therapy with Inhibitors of HMGB and Caspase for the Treatment of Inflammatory Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
| US-20100040607-A1 | Combination Therapy with Inhibitors of HMGB and Caspase for the Treatment of Inflammatory Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
| EP-1177168-B1 | CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA INC (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2004002401-A2 | CASPASE INHIBITORS FOR THE TREATMENT OF DISEASES AND CONDITIONS CAUSED BY EXPOSURE TO RADIONUCLIDES, BIOLOGICAL AGENTS, OR CHEMICAL AGENTS | CYTOVIA, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-6620782-B1 | Substituted 2-aminobenzamide caspase inhibitors and the use thereof | CYTOVIA, INC. | 2003-09-16 | — | — | US | disclosed |
| US-6620782-B1 | Substituted 2-aminobenzamide caspase inhibitors and the use thereof | CYTOVIA, INC. | 2003-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150343011-A1 | Treatment Of HIV-1 Infection And AIDS | CD4, CASP1, PYCARD | BACE1 76/4885BACE2 338/4885CASP1 2/4885 |
| US-20100040607-A1 | Combination Therapy with Inhibitors of HMGB and Caspase for the Treatment of Inflammatory Diseases | HMGB2, HMGB3, HMGB1 | BACE1 159/4885BACE2 186/4885CASP1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.